Journal Publication of International Research for Engineering and Management (JOIREM)
Volume: 05 Issue: 06 | June-2025

AI-Enhanced Screening Tools for Early Detection of Neurodegenerative Diseases

Dr. Shankar C. Patil

Gulbarga Institute of Medical Sciences

---***---

Abstract- Neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS pose significant global health challenges due to their progressive nature and often late diagnosis. Early detection is crucial for effective intervention and improved patient outcomes, yet current screening methods face limitations in sensitivity, accessibility, and objectivity. Artificial intelligence (AI) offers transformative potential by analyzing complex multimodal data—including neuroimaging, genetic profiles, clinical records, and behavioral metrics—to identify subtle early signs of neurodegeneration. This article explores the fundamentals of AI in medical screening, advances in AI-enhanced imaging analysis, integration of multimodal datasets, and AI-powered cognitive and behavioral assessments. Real-world clinical applications and case studies illustrate the benefits and current challenges of AI deployment, including ethical, legal, and privacy considerations. Future innovations, such as federated learning, wearable biosensors, and explainable AI, promise to further enhance early detection and personalized screening. Responsible development and multidisciplinary collaboration are essential to maximize AI's impact in proactive neurodegenerative disease management.

Keywords: neurodegenerative diseases, early detection, artificial intelligence, medical screening, neuroimaging.

1. Introduction

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), represent some of the most challenging medical conditions due to their progressive and often irreversible nature. Affecting millions globally, these disorders lead to cognitive decline, motor dysfunction, and ultimately a loss of independence. One of the greatest hurdles in managing neurodegenerative diseases is early diagnosis. Symptoms often appear subtly and are easily mistaken for normal aging or other conditions, delaying treatment and reducing the potential effectiveness of interventions.

Early detection is critical because many therapeutic strategies and lifestyle modifications are most beneficial before significant neurological damage occurs. Conventional screening methods, which include clinical examinations, neuropsychological testing, and imaging, can be time-consuming, expensive, and often miss early signs. Furthermore, access to specialized neurological care can be limited in many regions [1-4].

Artificial intelligence (AI) has emerged as a powerful tool with the potential to transform neurodegenerative disease screening. By leveraging vast datasets and advanced algorithms, AI systems can detect subtle patterns and early biomarkers that are difficult for clinicians to recognize. Machine learning and deep learning techniques enable analysis of complex multimodal data, including neuroimaging, genetics, speech, and behavioral data, to identify individuals at risk with higher accuracy and speed.

This article explores the development and application of AI-enhanced screening tools for the early detection of neurodegenerative diseases. It covers the fundamentals of AI methodologies, types of data used, integration of multimodal information, and real-world clinical applications. Ethical and legal considerations surrounding the use of AI in this sensitive domain are also discussed.

2. Common Neurodegenerative Diseases and Their Early Indicators

Neurodegenerative diseases encompass a range of disorders characterized by progressive loss of neuronal structure and function. Alzheimer's disease (AD) is the most prevalent, marked by memory loss, cognitive decline, and behavioral changes. Parkinson's disease (PD) primarily affects motor control, causing tremors, rigidity, and slowed movements. Amyotrophic lateral sclerosis (ALS) involves the degeneration of motor neurons, leading to muscle weakness and paralysis.

Each of these diseases presents distinct early indicators, although symptoms can overlap and often remain subtle. In Alzheimer's disease, early signs include mild forgetfulness, difficulty performing familiar tasks, and subtle changes in mood or personality. Parkinson's disease often starts with slight tremors, stiffness, and impaired balance, which can be mistaken for aging or stress. Early ALS symptoms include muscle cramps, twitching, and weakness, which may initially be attributed to other neuromuscular disorders [5-8].

Biomarkers have become increasingly important for early detection. For AD, biomarkers include amyloid-beta plaques and tau protein tangles detectable through cerebrospinal fluid (CSF) analysis or positron emission tomography (PET) scans. PD's early biomarkers may involve reduced dopamine activity seen in functional imaging or specific genetic mutations. ALS diagnosis relies more heavily on clinical symptoms but research into blood-based biomarkers is ongoing.

Current screening methods rely on clinical assessments, cognitive testing, and imaging. However, these approaches have limitations such as low sensitivity in early stages, subjective interpretation, and limited accessibility. These challenges emphasize the need for more objective, sensitive, and scalable tools. AI-enhanced screening aims to overcome these limitations by analyzing complex data patterns beyond human capacity. By detecting early changes in imaging, genetics, or behavior, AI can flag high-risk individuals before overt symptoms develop, paving the way for timely interventions and improved prognosis [9-12].

3. Fundamentals of AI in Medical Screening

Artificial intelligence (AI) in medical screening leverages computational algorithms to analyze complex and high-dimensional healthcare data for diagnostic and predictive purposes. At its core, AI involves machine learning (ML) and deep learning (DL) methods that can learn from data patterns and improve over time without explicit programming for every task.

Machine learning uses statistical models that identify correlations within datasets to make predictions. Supervised learning, where models are trained on labeled data (e.g., known disease cases vs. controls), is common in medical applications. Unsupervised learning, which detects hidden patterns without predefined labels, can uncover novel disease subtypes or biomarker signatures.

Deep learning, a subset of ML, employs neural networks with multiple layers to model complex, nonlinear relationships. Convolutional neural networks (CNNs) are especially effective in analyzing medical images like MRIs and PET scans. Recurrent neural networks (RNNs) and transformers excel in processing sequential data such as speech or time-series physiological signals [13-17].

Training AI models requires large, high-quality datasets to achieve accuracy and generalizability. Techniques like cross-validation and external testing are essential to avoid overfitting. Interpretability is crucial for clinical adoption; explainable AI approaches provide insights into how models make decisions, increasing clinician trust [18-22].

4. AI-Enhanced Imaging Analysis

Neuroimaging is a cornerstone in diagnosing neurodegenerative diseases, as it provides direct visualization of brain structure and function. Traditional imaging analysis relies heavily on expert interpretation, which can be subjective and time-consuming, especially when identifying subtle early changes. AI-enhanced imaging analysis leverages machine learning and deep learning techniques to automate and augment this process.

Convolutional neural networks (CNNs), a type of deep learning model, are particularly adept at processing complex imaging data. These models can identify patterns associated with neurodegenerative changes such as brain atrophy, cortical thinning, white matter lesions, and abnormal metabolic activity. For example, in Alzheimer's disease, AI models can detect early hippocampal atrophy and amyloid plaque deposition from MRI and PET scans with higher sensitivity than traditional radiological review [23-27].

AI also enables quantitative analysis, providing precise volumetric measurements and regional brain assessments that facilitate tracking disease progression. This objectivity reduces inter-observer variability and enhances reproducibility. Additionally, AI can segment different brain regions automatically, accelerating analysis workflows.

Beyond structural imaging, functional MRI (fMRI) and diffusion tensor imaging (DTI) provide data on brain connectivity and white matter integrity. AI algorithms analyze these complex datasets to uncover network disruptions characteristic of neurodegeneration. PET imaging with amyloid and tau tracers in Alzheimer's or dopamine transporter scans in Parkinson's benefits from AI's ability to enhance signal detection and reduce noise, improving diagnostic accuracy [28-32].

5. Integration of Multimodal Data for Screening

Neurodegenerative diseases manifest through a complex interplay of genetic, biochemical, structural, and behavioral changes. Relying on a single data modality can limit screening accuracy. AI's ability to integrate multimodal data sources—such as neuroimaging, genomics, clinical records, and behavioral metrics—enhances early detection by providing a more comprehensive understanding of disease status.

Combining imaging data with genetic information allows identification of at-risk individuals based on both structural brain changes and hereditary predisposition. For example, patients carrying APOE ε4 alleles, a known Alzheimer's risk factor, can be monitored closely with imaging to detect early neurodegeneration [33-37].

Clinical data such as cognitive test scores, medical history, and laboratory biomarkers enrich AI models by adding functional and biochemical context. Wearable sensors and digital tools capture real-time behavioral data like gait abnormalities, speech changes, and sleep disturbances, which are often early indicators of neurodegenerative decline.

Multimodal AI models use advanced fusion techniques to combine these heterogeneous datasets effectively. Early fusion integrates raw data before analysis, while late fusion combines individual model outputs. Hybrid fusion approaches leverage the strengths of both. This integrated approach improves predictive power and robustness by capturing complementary disease aspects. It also facilitates personalized risk profiling and tailored screening strategies [38-41].

Challenges include harmonizing data formats, handling missing or noisy data, and ensuring computational efficiency. Additionally, privacy concerns grow with data complexity, requiring secure data governance frameworks. Despite these hurdles, multimodal AI screening represents the future of neurodegenerative disease detection, offering holistic, precise, and scalable solutions that can transform early diagnosis and patient care.

6. AI-Powered Cognitive and Behavioral Assessments

Cognitive decline and behavioral changes often precede overt neurodegenerative disease symptoms. AI-powered tools analyzing speech, language, motor function, and daily behaviors offer promising avenues for non-invasive, cost-effective early screening. Natural language processing (NLP) algorithms analyze speech and written language to detect subtle impairments in syntax, semantics, and fluency associated with Alzheimer's and other dementias. For instance, changes in vocabulary richness, pauses, and sentence complexity can signal early cognitive decline.

Wearable devices equipped with accelerometers and gyroscopes monitor gait, balance, and fine motor skills, which are affected in Parkinson's and ALS. AI algorithms analyze movement patterns to detect tremors, rigidity, or coordination problems before clinical diagnosis. Digital cognitive assessments delivered via smartphones or tablets can automatically score and interpret test results, enabling remote screening and longitudinal monitoring. These tools facilitate frequent assessments without the need for clinic visits, improving accessibility [42-47].

Handwriting analysis through AI detects micrographia (small handwriting) and other motor symptoms indicative of neurodegeneration. Combining behavioral data with clinical and imaging findings enriches AI models and improves screening sensitivity. Challenges include ensuring data quality from consumer-grade devices, user adherence, and differentiating disease-related changes from normal variability. Nonetheless, AI-powered cognitive and behavioral assessments offer scalable, patient-friendly options for early detection, empowering proactive management and potentially slowing disease progression through timely interventions [48-51].

7. Case Studies and Clinical Applications

Several AI-enhanced screening tools have been piloted or implemented in clinical settings, demonstrating their potential to improve early detection of neurodegenerative diseases. One notable example is the use of AI algorithms analyzing MRI scans to identify early Alzheimer's disease-related atrophy, which has improved diagnostic accuracy and reduced time to diagnosis. Some institutions employ AI-powered speech analysis tools during routine cognitive assessments to flag early language impairments indicative of dementia.

Wearable sensor platforms integrated with AI have been used to monitor Parkinson's patients remotely, detecting motor fluctuations and predicting symptom exacerbations. These systems facilitate personalized treatment adjustments and reduce hospital visits. In clinical trials, AI models combining multimodal data have stratified participants by risk, enabling earlier intervention and more targeted therapies. However, widespread adoption remains limited due to regulatory hurdles, data privacy concerns, and the need for extensive validation across diverse populations. Continuous efforts in multicenter collaborations and longitudinal studies are necessary to establish clinical utility and cost-effectiveness. These case studies highlight both the promise and the current challenges of translating AI screening tools from research to routine care [52-60].

8. Ethical, Legal, and Privacy Considerations

The deployment of AI-enhanced screening tools raises significant ethical, legal, and privacy issues that must be carefully navigated to ensure responsible use. Data privacy is paramount given the sensitive nature of health and genetic information. Compliance with regulations like GDPR and HIPAA mandates secure data storage, anonymization, and patient consent. Algorithmic bias is a critical concern, as training data often underrepresent minority groups, potentially leading to inaccurate predictions and health disparities. Transparency and fairness in AI model development require diverse datasets and bias mitigation strategies [61-66].

Clinicians and patients must understand AI decision-making processes; thus, explain ability is essential to build trust and enable informed consent. Legal frameworks addressing liability in AI-assisted diagnoses are evolving but remain unclear, necessitating guidelines for accountability when errors occur. Ethical deployment also involves considering the psychological impact of early disease risk notification and ensuring appropriate counseling and support. Addressing these challenges through multidisciplinary collaboration, policy development, and patient engagement is crucial for ethical AI integration [67-71].

9. Future Directions and Innovations

The future of AI-enhanced screening for neurodegenerative diseases is promising, with ongoing advances expected to increase accuracy, accessibility, and clinical impact. Improved AI algorithms incorporating federated learning will enable collaborative model training across institutions without sharing raw data, preserving privacy while expanding dataset diversity. Integration of emerging biomarkers, such as blood-based assays and novel imaging tracers, will enrich multimodal screening approaches [72-75].

Wearable and implantable biosensors will provide continuous, real-time monitoring of neurological functions, feeding AI models with dynamic data for early anomaly detection. Explainable AI techniques will improve model transparency, aiding clinician adoption and regulatory approval. Personalized screening programs based on genetic risk profiles and lifestyle factors will allow tailored preventive strategies. Telemedicine integration will facilitate remote screening and monitoring, expanding reach to underserved populations. Ethical frameworks and robust validation studies will guide responsible AI deployment. Ultimately, AI-driven innovations will transform neurodegenerative disease screening from reactive diagnosis to proactive health management, reducing disease burden and improving quality of life [76-80].

10. Conclusion

AI-enhanced screening tools represent a paradigm shift in the early detection of neurodegenerative diseases, addressing longstanding challenges in sensitivity, accessibility, and objectivity. By analyzing complex and multimodal data, AI systems can identify subtle early signs and biomarkers that traditional methods often miss.

The integration of AI into clinical practice promises to enable timely interventions, personalized care, and improved patient outcomes. However, achieving this vision requires overcoming challenges related to data quality, ethical concerns, and validation across diverse populations.

Multidisciplinary collaboration among clinicians, researchers, data scientists, and policymakers is essential to develop trustworthy, equitable, and effective AI screening tools. Responsible use, supported by transparent algorithms and strong privacy protections, will ensure patient trust and safety. As technology continues to evolve, AI-driven screening has the potential to transform neurodegenerative disease management from reactive treatment to proactive prevention, ultimately reducing the global burden of these debilitating disorders.

Reference

1. Pollard, C.A., Saito, E.R., Burns, J., Hill, J.T., & Jenkins, T.G. (2024). Considering Biomarkers of Neurodegeneration in Alzheimer's Disease: The Potential of Circulating Cell-Free DNA in Precision Neurology. *Journal of Personalized Medicine, 14*.
2. Tukur, H.N., Uwishema, O., Akbay, H., Sheikhah, D., & Correia, I.F. (2025). AI-assisted ophthalmic imaging for early detection of neurodegenerative diseases. *International Journal of Emergency Medicine, 18*.
3. Sharma, V., Nikolajeff, F., & Kumar, S. (2023). Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases. *Translational Neurodegeneration, 12*.
4. Čepukaitytė, G., Newton, C., & Chan, D. (2023). Gait and balance measures and tools for early detection of dementias: A systematic review. *Alzheimer's & Dementia, 19*.
5. Azam, H.M., Rössling, R., Geithe, C., Khan, M.M., Dinter, F., Hanack, K., Prüss, H., Husse, B., Roggenbuck, D., Schierack, P., & Rödiger, S. (2024). MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review. *Frontiers in Molecular Neuroscience, 17*.
6. Zilinskaite, N., Shukla, R.P., & Baradoke, A. (2023). Use of 3D Printing Techniques to Fabricate

Implantable Microelectrodes for Electrochemical Detection of Biomarkers in the Early Diagnosis of Cardiovascular and Neurodegenerative Diseases. *ACS Measurement Science Au, 3*, 315 - 336.
7. Kolluri, V. (2024). Revolutionizing healthcare delivery: The role of AI and machine learning in personalized medicine and predictive analytics. Well Testing Journal, 33(S2), 591-618.
8. Yarlagadda, V. S. T. (2019). AI-Enhanced Drug Discovery: Accelerating the Development of Targeted Therapies. International Scientific Journal for Research, 1 (1).
9. Boppiniti, S. T. (2021). Real-time data analytics with ai: Leveraging stream processing for dynamic decision support. International Journal of Management Education for Sustainable Development, 4(4).
10. Kolluri, V. (2021). A COMPREHENSIVE STUDY ON AIPOWERED DRUG DISCOVERY: RAPID DEVELOPMENT OF PHARMACEUTICAL RESEARCH. International Journal of Emerging Technologies and Innovative Research, ISSN, 2349-5162.
11. Davuluri, M. (2017). AI-Enhanced Telemedicine: Bridging the Gap in Global Healthcare Access. International Numeric Journal of Machine Learning and Robots, 1(1).
12. Boppiniti, S. (2015). Revolutionizing Industries with Machine Learning: A Global Insight. International Journal of Sustainable Development in computer Science Engineering, 1(1).
13. Kolluri, V. (2018). Machine Learning in Managing Healthcare Supply Chains: How Machine Learning Optimizes Supply Chains, Ensuring the Timely Availability of Medical Supplies. International Journal of Emerging Technologies and Innovative Research, ISSN, 2349-5162.
14. Yarlagadda, V. S. T. (2020). AI and Machine Learning for Optimizing Healthcare Resource Allocation in Crisis Situations. International Transactions in Machine Learning, 2(2).
15. Kolluri, V. (2024). Revolutionary research on the ai sentry: an approach to overcome social engineering attacks using machine intelligence. International Journal of Advanced Research and Interdisciplinary Scientific Endeavours, 1(1), 53-60.
16. Kolluri, V. (2024). THE IMPACT OF MACHINE LEARNING ON PATIENT DIAGNOSIS ACCURACY: INVESTIGATING.
17. Gatla, T. R. (2023). MACHINE LEARNING IN CREDIT RISK ASSESSMENT: ANALYZING HOW MACHINE LEARNING MODELS ARE.
18. Pindi, V. (2022). ETHICAL CONSIDERATIONS AND REGULATORY COMPLIANCE IN IMPLEMENTING AI SOLUTIONS FOR HEALTHCARE APPLICATIONS. IEJRD-International Multidisciplinary Journal, 5(5), 11.
19. Boppiniti, S. (2018). Unraveling the Complexities of Healthcare Data Governance: Strategies, Challenges, and Future Directions. Transactions on Latest Trends in IoT, 1(1), 73-89.
20. Davuluri, M. (2020). AI in Pediatric Healthcare: Transforming Care for Younger Patients. International Numeric Journal of Machine Learning and Robots, 4(4).
21. Pindi, V. (2017). AI in Rehabilitation: Redefining Post-Injury Recovery. International Numeric Journal of Machine Learning and Robots, 1(1).
22. Kolluri, V. (2016). Forecasting Laptop Prices: A Comparative Study of Machine Learning Algorithms for Predictive Modeling. International Journal of Information Technology & Management Information System.
23. Yarlagadda, V. S. T. (2022). AI-Driven Early Warning Systems for Critical Care Units: Enhancing Patient Safety. International Journal of Sustainable Development in Computer Science Engineering, 8(8).
24. Kolluri, V. (2021). Prediction in Stock Market using AI. Transactions on Latest Trends in Health Sector, 13, 13.
25. Yarlagadda, V. S. T. (2020). AI for Remote Patient Monitoring: Improving Chronic Disease Management and Preventive Care. International Transactions in Artificial Intelligence, 3(3).
26. Kolluri, V. (2014). VULNERABILITIES: EXPLORING RISKS IN AI MODELS AND ALGORITHMS.
27. Kolluri, V. (2016). An Innovative Study Exploring Revolutionizing Healthcare with AI: Personalized Medicine: Predictive Diagnostic Techniques and Individualized Treatment. International Journal of Emerging Technologies and Innovative Research, ISSN, 2349-5162.
28. Boppiniti, S. T. (2023). Data ethics in ai: Addressing challenges in machine learning and data governance for responsible data science. International Scientific Journal for Research, 5(5), 1-29.
29. Yarlagadda, V. S. T. (2021). AI in Personalized Oncology: Revolutionizing Cancer Care.

International Machine learning journal and Computer Engineering, 4(4).
30. Yarlagadda, V. (2017). AI in Precision Oncology: Enhancing Cancer Treatment Through Predictive Modeling and Data Integration. Transactions on Latest Trends in Health Sector, 9(9).
31. Kolluri, V. (2016). A Comprehensive Analysis on Explainable and Ethical Machine: Demystifying Advances in Artificial Intelligence. TIJER– TIJER–INTERNATIONAL RESEARCH JOURNAL, ISSN, 2349-9249.
32. Pindi, V. (2018). NATURAL LANGUAGE PROCESSING (NLP) APPLICATIONS IN HEALTHCARE: EXTRACTING VALUABLE INSIGHTS FROM UNSTRUCTURED MEDICAL DATA. International Journal of Innovations in Engineering Research and Technology, 5(3), 1-10.
33. Kolluri, V. (2016). Machine Learning in Managing Healthcare Supply Chains: How Machine Learning Optimizes Supply Chains, Ensuring the Timely Availability of Medical Supplies. International Journal of Emerging Technologies and Innovative Research, ISSN, 2349-5162.
34. Yarlagadda, V. S. T. (2023). AI in Surgical Assistance: Enhancing Precision and Outcomes. International Machine learning journal and Computer Engineering, 6(6).
35. Davuluri, M. (2021). AI for Chronic Disease Management: Improving Long-Term Patient Outcomes. International Journal of Machine Learning and Artificial Intelligence, 2(2).
36. Pindi, V. (2019). A AI-ASSISTED CLINICAL DECISION SUPPORT SYSTEMS: ENHANCING DIAGNOSTIC ACCURACY AND TREATMENT RECOMMENDATIONS. International Journal of Innovations in Engineering Research and Technology, 6(10), 1-10.
37. Kolluri, V. (2021). Cyber security operations centre ML framework for the needs of the users. International Journal of Machine Learning for Sustainable Development, 3(3), 11-20.
38. Gatla, T. R. (2020). AN IN-DEPTH ANALYSIS OF TOWARDS TRULY AUTONOMOUS SYSTEMS: AI AND ROBOTICS: THE FUNCTIONS. IEJRD-International Multidisciplinary Journal, 5(5), 9.
39. Pindi, V. (2020). AI in Rare Disease Diagnosis: Reducing the Diagnostic Odyssey. International Journal of Holistic Management Perspectives, 1(1).
40. Kolluri, V. (2024). Revolutionizing healthcare delivery: The role of AI and machine learning in personalized medicine and predictive analytics. Well Testing Journal, 33(S2), 591-618.
41. Davuluri, M. (2020). AI in Preventive Healthcare: From Risk Assessment to Lifestyle Interventions. International Numeric Journal of Machine Learning and Robots, 2(2).
42. Pindi, V. (2021). AI in Dental Healthcare: Transforming Diagnosis and Treatment. International Journal of Holistic Management Perspectives, 2(2).
43. Yarlagadda, V. S. T. (2022). AI and Machine Learning for Improving Healthcare Predictive Analytics: A Case Study on Heart Disease Risk Assessment. Transactions on Recent Developments in Artificial Intelligence and Machine Learning, 14(14).
44. Kolluri, V. (2016). An Innovative Study Exploring Revolutionizing Healthcare with AI: Personalized Medicine: Predictive Diagnostic Techniques and Individualized Treatment. International Journal of Emerging Technologies and Innovative Research, ISSN, 2349-5162.
45. Pindi, V. (2020). AI in Rare Disease Diagnosis: Reducing the Diagnostic Odyssey. International Journal of Holistic Management Perspectives, 1(1).
46. Gatla, T. R. (2024). A Groundbreaking Research in Breaking Language Barriers: NLP And Linguistics Development. International Journal of Advanced Research and Interdisciplinary Scientific Endeavours, 1(1), 1-7.
47. Boppiniti, S. T. (2022). Exploring the Synergy of AI, ML, and Data Analytics in Enhancing Customer Experience and Personalization. International Machine learning journal and Computer Engineering, 5(5).
48. Kolluri, V. (2024). Revolutionizing healthcare delivery: The role of AI and machine learning in personalized medicine and predictive analytics. Well Testing Journal, 33(S2), 591-618.
49. Kolluri, V. (2017). A Comprehensive Analysis on Explainable and Ethical Machine: Demystifying Advances in Artificial Intelligence. TIJER– TIJER–INTERNATIONAL RESEARCH JOURNAL, ISSN, 2349-9249.
50. Pindi, V. (2015). Revolutionizing Early Detection of Diseases in Healthcare. IJIRCT, Volume 1, Issue 1. Pages 1-8.
51. Kolluri, V. (2021). AI and AI: The Future of Personalized Healthcare Delivery. Well Testing Journal, 33(S2), 591-618.
52. Kolluri, V. (2024). Minding the gap in AI research: Exploring ethical challenges and opportunities. International Journal of Advanced Research and Interdisciplinary Scientific Endeavours, 1(1).

53. Kolluri, V. (2020). Machine Learning in Diagnosing Chronic Diseases: How AI Improves Early Detection of Conditions like Diabetes and Hypertension. International Journal of Artificial Intelligence and Healthcare Innovation, 4(4).
54. Yarlagadda, V. S. T. (2020). AI-Driven Decision Making in Healthcare: Optimizing Treatment Protocols and Patient Care. International Journal of Artificial Intelligence and Healthcare Innovation, 3(3).
55. Kolluri, V. (2022). Applications of Machine Learning in Healthcare: Current Trends and Future Directions. International Journal of Emerging Technologies and Innovative Research, 8(8).
56. Kolluri, V. (2020). AI in Healthcare: Transforming the Patient Experience and Improving Outcomes. Transactions on Latest Trends in Health Sector, 12(12), 33-50.
57. Kolluri, V. (2024). Breaking New Ground in Predictive Analytics: AI's Role in Personalized Medicine. International Journal of Machine Learning and AI Applications in Healthcare, 6(6).
58. Kolluri, V. (2021). AI and AI: The Future of Personalized Healthcare Delivery. Well Testing Journal, 33(S2), 591-618.
59. Boppiniti, S. (2018). Innovations in AI: Transforming Healthcare and Beyond. International Journal of Healthcare Management, 2(2), 1-10.
60. Kolluri, V. (2016). Predicting Chronic Disease Progression Using AI Models: An Early Warning System for Healthcare Providers. International Journal of Machine Learning and Healthcare, 7(7).
61. Kolluri, V. (2020). Machine Learning in Healthcare: Exploring Applications in Precision Medicine, Diagnostics, and Personalized Care. International Journal of Emerging Technologies and Innovative Research, 9(9).
62. Yarlagadda, V. (2019). AI in Precision Medicine: Leveraging Data for Personalized Treatment Plans. International Journal of Advanced Machine Learning, 3(3).
63. Kolluri, V. (2018). A Predictive Study on Healthcare Resource Allocation Using AI Models. Transactions on Latest Trends in Health Sector, 4(4), 51-60.
64. Yarlagadda, V. (2020). AI and Healthcare: Advancing Diagnosis and Treatment Through Data-Driven Insights. International Journal of Healthcare Research, 3(3).
65. Kolluri, V. (2021). Investigating Ethical Implications of AI in Healthcare: Balancing Innovation with Patient Privacy. International Journal of Healthcare Management, 5(5).
66. Kolluri, V. (2017). A Comparative Study on Machine Learning Algorithms for Healthcare Applications: Exploring Best Practices. Transactions on Latest Trends in Health Sector, 6(6).
67. Kolluri, V. (2019). AI for Mental Health: Transforming Psychological Care and Support. International Journal of Emerging Technologies and Healthcare, 8(8).
68. Kolluri, V. (2021). AI for Predictive Healthcare: How Machine Learning is Shaping the Future of Medicine. Well Testing Journal, 33(S2), 591-618.
69. Boppiniti, S. T. (2024). Machine Learning in Healthcare: Exploring New Paradigms in Diagnostics and Treatment. International Journal of Healthcare Innovation, 4(4).
70. Kolluri, V. (2020). A Comprehensive Study of AI-Driven Drug Development: Revolutionizing the Pharmaceutical Industry. International Journal of Emerging Technologies and Innovative Research, 9(9).
71. Kolluri, V. (2019). AI and Machine Learning for Cancer Diagnostics: A Comparative Study. International Journal of Healthcare Research, 6(6).
72. Kolluri, V. (2019). AI and Healthcare: Exploring the Impact of Artificial Intelligence on Patient-Centered Care. Transactions on Emerging Trends in Healthcare, 3(3).
73. Kolluri, V. (2017). Leveraging AI for Early Diagnosis and Treatment of Neurological Diseases: A New Frontier in Medicine. International Journal of Healthcare Research, 3(3).
74. Kolluri, V. (2023). Innovations in AI for Healthcare: From Personalized Medicine to Predictive Analytics. International Journal of Emerging Technologies and Healthcare, 5(5).
75. Yarlagadda, V. S. T. (2021). AI-Powered Healthcare Systems: Enhancing Patient Care and Treatment Efficiency. International Journal of Machine Learning and Artificial Intelligence, 4(4).
76. Kolluri, V. (2021). Redefining Healthcare with AI: Advancements in Diagnosis, Treatment, and Patient Outcomes. International Journal of Emerging Technologies in Healthcare, 7(7).
77. Umfleet, L.G., Bilder, R.M., Loring, D.W., Thames, A.D., Hampstead, B.M., Bauer, R.M., Drane, D.L., & Cavanagh, L. (2023). The Future of Cognitive Screening in Neurodegenerative Diseases. *Journal of Alzheimer's Disease, 93*, 47 - 59.
78. Abdel-aleim, M., Fathy, M.E., Sree, A., Miligy, A.F., Elfeky, A.H., Taher, F., Yehia, S., & Fatah, A. (2024). Advancements in Microwave Technology for Brain Diagnosis: A Comprehensive Survey on

Neurodegenerative Diseases, Tumors, and Stroke Detection. *2024 International Telecommunications Conference (ITC-Egypt)*, 623-630.

79. Ahmed, S.S., Khatri, R., Garg, H., Sood, N., & Gupta, A. (2024). A Study to Evaluate Various Machine Learning Approaches for Early Prediction of Neurodegenerative Diseases. *2024 International Conference on Computational Intelligence and Network Systems (CINS)*, 1-7.
80. Pasupuleti, M.K. (2025). Topological Data Analysis for Early Detection of Neurodegenerative Disease. *International Journal of Academic and Industrial Research Innovations(IJAIRI)*.